ATE247709T1 - 3'utr des menschliches prohibitin-gens - Google Patents

3'utr des menschliches prohibitin-gens

Info

Publication number
ATE247709T1
ATE247709T1 AT96921425T AT96921425T ATE247709T1 AT E247709 T1 ATE247709 T1 AT E247709T1 AT 96921425 T AT96921425 T AT 96921425T AT 96921425 T AT96921425 T AT 96921425T AT E247709 T1 ATE247709 T1 AT E247709T1
Authority
AT
Austria
Prior art keywords
utr
prohibitin gene
human prohibitin
human
gene
Prior art date
Application number
AT96921425T
Other languages
English (en)
Inventor
Orco Robert T Dell
Eldon R Jupe
J Keith Mcclung
Xiao-Tie Liu
Robert L King
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE247709T1 publication Critical patent/ATE247709T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AT96921425T 1995-06-07 1996-06-07 3'utr des menschliches prohibitin-gens ATE247709T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,486 US5922852A (en) 1995-06-07 1995-06-07 3' untranslated region of the human prohibitin gene
PCT/US1996/009687 WO1996040919A1 (en) 1995-06-07 1996-06-07 3' utr of the human prohibitin gene

Publications (1)

Publication Number Publication Date
ATE247709T1 true ATE247709T1 (de) 2003-09-15

Family

ID=23879728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921425T ATE247709T1 (de) 1995-06-07 1996-06-07 3'utr des menschliches prohibitin-gens

Country Status (9)

Country Link
US (3) US5922852A (de)
EP (1) EP0837935B1 (de)
AT (1) ATE247709T1 (de)
AU (1) AU713814B2 (de)
CA (1) CA2224014A1 (de)
DE (1) DE69629570T2 (de)
DK (1) DK0837935T3 (de)
ES (1) ES2205046T3 (de)
WO (1) WO1996040919A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
AU774116B2 (en) * 1995-06-07 2004-06-17 Oklahoma Medical Research Foundation Use of prohibitin RNA in treatment of cancer
CA2269664C (en) * 1996-11-07 2007-08-07 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
DE69828647T2 (de) * 1997-11-06 2005-12-01 Oklahoma Medical Research Foundation, Oklahoma Diagnostisches assay zur krebsanfälligkeit
EP1100892B1 (de) * 1998-07-24 2008-04-09 Oklahoma Medical Research Foundation Verwendung von prohibitin-rns in krebsbehandlung
ATE462725T1 (de) * 1998-08-25 2010-04-15 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins
US7273855B2 (en) * 1999-07-24 2007-09-25 Oklahoma Medical Research Foundation Use of prohibitin RNA in treatment of cancer
US20040002071A1 (en) * 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
EP2500437B1 (de) 2003-01-21 2016-11-30 PTC Therapeutics, Inc. Verfahren zur Identifizierung von Verbindungen zur Modulation der Expression von Genen mit Abhängigkeit einer untranslatierten Region sowie Verfahren zu deren Verwendung
ATE466104T1 (de) * 2003-03-19 2010-05-15 Univ British Columbia Als indikatoren zur patientenprognose geeignete haplotypen von plasminogenaktivator-inhibitor-1 (pai-1)
JP4634371B2 (ja) * 2003-03-27 2011-02-16 ピーティーシー セラピューティクス，インコーポレーテッド ｔＲＮＡスプライシングエンドヌクレアーゼに標的化する化合物の同定方法、および該化合物の抗増殖剤としての使用
WO2004087884A2 (en) * 2003-03-27 2004-10-14 Ptc Therapeutics, Inc TARGETING ENZYMES OF THE tRNA SPLICING PATHWAY FOR IDENTIFICATION OF ANTI-FUNGAL AND/OR ANTI-PROLIFERATIVE MOLECULES
EP1613159A4 (de) * 2003-03-27 2007-08-01 Ptc Therapeutics Inc Verfahren zur identifikation von verbindungen mit einer trna-splicenden endonuklease als angriffsort, sowie verwendungen für diese verbindungen als antifungale mittel
CA2531321A1 (en) * 2003-07-02 2005-01-13 Ptc Therapeutics, Inc. Rna processing protein complexes and uses thereof
WO2005049868A1 (en) * 2003-11-17 2005-06-02 Pct Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating her2 expression
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene

Also Published As

Publication number Publication date
EP0837935A1 (de) 1998-04-29
DK0837935T3 (da) 2003-12-15
EP0837935B1 (de) 2003-08-20
AU713814B2 (en) 1999-12-09
DE69629570D1 (de) 2003-09-25
US5776738A (en) 1998-07-07
CA2224014A1 (en) 1996-12-19
DE69629570T2 (de) 2004-06-17
US7259251B1 (en) 2007-08-21
WO1996040919A1 (en) 1996-12-19
ES2205046T3 (es) 2004-05-01
US5922852A (en) 1999-07-13
AU6265396A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
IL117177A (en) Benzopyran-containing compounds and their use in manufacture of medicaments for treatment of estrogen sensitive diseases such as endometrical cancer
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
GB9613003D0 (en) N-oxides of morpholine derivatives and their use as therapeutic agents
HU9602583D0 (en) Gel for treatment of skin diseases and for disinfection of the skin
NO994014L (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
EP0888458A4 (de) Kombination von pkc-inhibitoren und therapeutischen agenzien zur behandlung von krebs
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
DK0687184T3 (da) Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
NZ512289A (en) Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
FI973185L (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
EP0907720A4 (de) Kombinierte radiotherapie und immuntherapie zur behandlung von krebs
NO964330L (no) Farmasöytisk sammensetning for terapeutisk behandling av tardiv dyskinesi og anvendelse derav

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0837935

Country of ref document: EP

REN Ceased due to non-payment of the annual fee